Tanta University
Tanta, El Gharbia, 31111, Egypt
NCT Number: NCT04288440
31 patients were included in the study,15 cases with ERM in silicone filled eyes and 16 eyes with idiopathic ERM
Looking for future studies?
Notify Me42 year–64 year
All sexes
Interventional
Not applicable
Tanta, El Gharbia, 31111, Egypt
This is a prospective study that included 31 patients and was performed in Tanta University Eye Hospital in cooperation with the Pathology Department, Tanta University, between January 2018 and June 2019. The approval of the ethical committee of the Faculty of Medicine in Tanta University was obtained, and the study was conducted in accordance with the 1964 Helsinki Declaration and its later amendment. A detailed informed written consent was signed by all study participants. The research is not funded by the university or any organization or entity.
Fifteen cases had pars plana vitrectomy for rhegmatogenous retinal detachment nine months earlier with ERM detected by OCT one day before silicone oil removal. The other 16 cases matched for age and gender with idiopathic ERM and were included as a control. Histopathological features of the ERMs were compared between the two groups.
All patients have undergone complete ophthalmic evaluation including: best corrected visual acuity (BCVA) by Snellen chart that was converted to log MAR for statistical analysis, anterior segment examination by slit lamp, posterior segment examination by slit lamp bimicroscopy using +78 D lens and indirect Ophthalmoscopy, and Spectral domain optical coherence tomography (SD-OCT) (Spectralis; Heidelberg Engineering,Heidelberg, Germany) was performed for all patients before surgery.
The investigators excluded patients with previous intraocular surgery (except cataract surgery) for the control group, diabetes mellitus/diabetic retinopathy, coincident retinal pathology as choroidal neovascular membrane and age related macular degeneration, previous laser photocoagulation, intravitreal injection of Triamcinolone Acetonide or antivascular endothelial growth factor (anti-VEGF) agents, prior intra-ocular inflammation, retinal degenerations, neovascularization or rubeosis and vascular disorders e.g. retinal vein or artery occlusion.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-
Exclusion criteria
the investigator excluded 1-patients with previous intraocular surgery (except cataract surgery) for the control group.
2- Diabetes mellitus/diabetic retinopathy. 3-Coincident retinal pathology as choroidal neovascular membrane and age related macular degeneration.
4-previous laser photocoagulation, intravitreal injection of Triamcinolone Acetonide or antivascular endothelial growth factor (anti-VEGF) agents.
5- prior intra-ocular inflammation, retinal degenerations.
6-Neovascularization or rubeosis and vascular disorders e.g. retinal vein or artery occlusion.
-
Removal of epiretinal membrane and ILM
Other names: Invasive procedure
Pars plana vitrectomy
Time frame: 6 months
Percentage of glial fibrillary acid protein positive cells and number of cluster of differentiation cells in idiopathic and silicone oil ERM
Tanta University
Other
Pathological Features of Epiretinal Membranes in Silicone Filled Eyes
Acronym: RD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03970655
Chronic Rhinosinusitis (Diagnosis), Disease
Gainesville, Florida, United States
View Trial DetailsNCT07731217
Asthma, Asthma (Diagnosis)
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT02328963
Cytomegalovirus Infection, Cytomegalovirus Infections
Bordeaux, France
View Trial DetailsNCT05468619
DNA Virus Infections, Disease
Birmingham, Alabama, United States
View Trial Details